GSK wins approval from the U.S. FDA for shingles vaccine
Date: 2017-10-24   Author: Pankaj Singh  Category: #market

GSK wins approval from the U.S. FDA for shingles vaccine

GlaxoSmithKline (GSK) PLC, the British pharma giant, has apparently received the awaited green signal from the U.S. Food and Drug Administration for its new and enhanced shingles vaccine. As per reports, the Brentford-based joint venture is also hoping to win approval for another of its key products this year.

Sources claim that GSK’s shingles vaccine stood better than Zostavax, a product of Merck & Co, in the clinical trials carried out by the FDA. The fact that Shingrix - GSK’s shingles vaccine, has been approved by the FDA is one of the important acquittals of the company’s product pipeline. The vaccine is touted to emerge as one of most pivotal products in GSK’s portfolio, and has been claimed by analysts to collect a revenue of USD 1.36 billion by the end of 2023.

A month prior to the shingles vaccine approval, GSK made it to the headlines for having received the green signal for its three-in-one inhaler, designed to be used in chronic lung disease treatment. Post a series of approvals, further on, GSK hopes to launch a dual regimen drug for HIV. The U.S. regulatory bodies are apparently planning to carry out clinical trials for this groundbreaking drug regimen by the end of 2017.

Currently, it is being reported that Shingrix and Zostavax are the only available vaccines for shingles prevention, though the former has been declared to be more effective. Apart from the FDA, an advisory committee of the United States Centers for Disease Control and Prevention on immunization practices has also planned to cast its opinion regarding Shringrix.

Most analysts, it is reported, have been expecting a positive affirmation on Shringrix from the advisory committee, so that it can be liberally used for older adults. The expectation specifically borders on the fact that the elderly are more vulnerable to shingles and chicken pox owing to the recurrence of the varicella-zoster virus among older people.

For the record, GSK has also secured recommendation from the UK cost authorities to carry out a USD 700,000 worth gene therapy over the ‘bubble boy’ disease.



About Author


Pankaj Singh

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More from Pankaj


Post Recommendents

Worldwide N-Methylethanolamine Market Forecast 2021-2026 Growth Drivers, Regional Outlook
Author: Ashwin Naphade

Market Study Report, LLC, has added an exhaustive research study of the ' N-Methylethanolamine market', detailing every single market driver and intricately analyzing the business vertical. This ' N-Methylethanolamine market' study...


2026 Projections: Transient Voltage Suppressor Diodes Market Report by Type, Application and Regional Outlook
Author: Ashwin Naphade

The ' Transient Voltage Suppressor Diodes market' report added recently by Market Study Report, LLC, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a prec...


Worldwide Oxygen Regulator Market Study for 2021 to 2026 providing information on Key Players, Growth Drivers and Industry challenges
Author: Ashwin Naphade

The ' Oxygen Regulator market' report Added by Market Study Report, LLC, enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive i...